세계의 안구 임플란트 시장 규모는 2023년에 50억 6,043만 달러, 2030년 65억 6,146만 달러에 달하며, 2024-2030년의 예측 기간에 CAGR로 4.51%의 성장이 전망됩니다. 시장은 녹내장, 백내장, 노안, 근시 등 다양한 안질환의 증례 증가, 세계 노년 인구의 부담 증가, 제품의 안전성과 생체적합성을 한층 더 높이는 기술의 진보 등의 요인에 의해 성장이 전망되고 있으며, 예측 기간(2024-2030년)에 시장 큰 매출 성장이 전망됩니다.
안구 임플란트 시장 역학
안구 임플란트 시장의 주목할 만한 촉진요인 중 하나는 백내장, 녹내장, 노안, 근시 등 안질환의 유병률 상승입니다. 예를 들면 세계보건기구(WHO)(2023)에 따르면 근시 또는 원시 유병자는 전 세계에서 22억 명에 달하며, 이 유병자의 절반 가까이가 시력 장애를 예방할 수 있었음에도 불구하고 아직 해결되지 않았다고 합니다. 같은 자료에 따르면 2020년 미치료 백내장과 녹내장 유병자는 각각 9,400만 명과 770만 명에 달할 전망입니다. 또한 근시, 노안 등의 굴절이상도 앞으로 증가할 것으로 예상되고 있습니다. 예를 들어 International Myopia Institute(2023)에 따르면 현재 전 세계 30%가 근시이며, 2050년까지 근시 인구는 50%로 증가하여 50억 명에 달할 것으로 예측했습니다. 앞서 언급 한 자료에 따르면 근시는 동아시아 및 동남아시아에서 더 흔하며 한국, 중국, 일본과 같은 국가에서는 80% - 90%의 유병률이 있다고 언급했습니다. 노안의 경우 세계보건기구(WHO)가 World Report on Vision(2019)에서 인용한 데이터에 따르면 2018년 전 세계에서 약 18억 건의 노안이 발생했다고 합니다.
또한 백내장, 노인성 황반변성(AMD), 녹내장, 당뇨병성 망막증, 노안 등 여러 안질환에 걸리기 쉬운 노년층 인구 증가는 안구 임플란트 시장을 더욱 가속화할 것으로 예상되며, 세계보건기구(WHO)(2023년)의 데이터에 따르면 2020년 전 세계에서 약 10억 명이 60세 이상이었다고 합니다. 이상이었습니다. 위 자료는 2050년까지 60세 이상 노년층 인구가 두 배로 증가하여 약 21억 명에 달할 것으로 예측했습니다. 또한 80세 이상 인구는 2020-2050년 3배 증가하여 4억 2,600만 명에 달할 것으로 추정됩니다.
그러나 프리미엄 렌즈의 커버리지 부족과 수술 및 장비에 따른 합병증은 안구 임플란트 시장을 억제하는 요인으로 작용할 수 있습니다.
안구 임플란트 시장은 COVID-19 감염의 사슬을 끊기 위해 필요한 조치로 봉쇄 조치가 시행됨에 따라 시장 성장의 단기적인 후퇴가보고되었으며, COVID-19 팬데믹으로 인해 의료 서비스와 의료 절차의 대규모 재편이 이루어졌습니다. 많은 국가에서 COVID-19 위기 동안 워크플로우를 간소화하기 위해 응급의료의 필요성에 따라 의료 절차를 분리하고 선택적으로 간주되는 다양한 의료 절차가 중단되었습니다. 예를 들어 2020년 3월 미국안과학회(American Academy of Ophthalmology, AAO)는 안과 의사들에게 모든 일상적인 진료를 중단하고 응급환자로만 진료를 제한할 것을 권고했습니다. 권고했습니다. 또한 봉쇄 기간 중 안구 임플란트 조달이 어려워져 안구내 수술이 감소했습니다. 따라서 제품 수요는 평소보다 감소했습니다. 그러나 의료 부문을 포함한 산업 전반의 활동 재개는 안구 임플란트 시장을 촉진하고 있으며, 2024-2030년의 예측 기간 중 성장을 가속할 것으로 예상됩니다.
안구 임플란트 시장 부문별 분석
안구 임플란트 시장 유형 부문에서는 안구내 렌즈 카테고리가 2022년 78%로 가장 높은 매출 점유율을 차지했습니다.
이는 인공수정체의 다양한 특성, 기술적 우위, 공동 연구 및 규제 당국의 승인과 같은 제품 개발 활동 증가에 기인합니다.
세계의 안구 임플란트 시장에 대해 조사분석했으며, 시장 규모와 예측, 촉진요인과 과제, 기업과 제품 개요 등을 제공하고 있습니다.
Ocular Implants Market By Type (Intraocular Lenses, Corneal Implants, Glaucoma Implants, Artificial Iris, And Others) By Material (Biodegradable And Non-Biodegradable), By Application (Cataract, Glaucoma Surgery, Oculoplasty, Drug Delivery, Macular Degeneration, And Others), By End-User (Hospitals, Eye Speciality Clinics, And Ambulatory Surgical Centres) and by geography is estimated to register a growth at a remarkable CAGR forecast during 2024-2030 owing to surge in the cases of various eye disorders and growing burden of geriatric population globally
The global ocular implants market was valued at USD 5,060.43 million in 2023, growing at a CAGR of 4.51% during the forecast period from 2024 to 2030 to reach USD 6,561.46 million by 2030. The ocular implants market is slated to witness growth owing to factors such as a rise in the cases of various eye disorders like glaucoma, cataract, presbyopia, and myopia among others, escalating burden of the geriatric population globally, and the increasing technological advancements to further enhance product safety and biocompatibility is expected to result in appreciable revenue growth in the ocular implants market during the forecast period (2024-2030).
Ocular Implants Market Dynamics:
One of the noteworthy drivers of the ocular implant market is the rise in the prevalence of eye disorders such as cataracts, glaucoma, presbyopia, and myopia. For instance, according to the World Health Organization (2023), the prevalence of population having near or distance vision impairment stands at a staggering figure of 2.2 billion globally, with which almost half of the affected people could have prevented vision impairment, or the cases have not yet been addressed. According to the same source, the prevalence rate of unaddressed cataracts and glaucoma in the year 2020 were 94 million and 7.7 million respectively. The number of refractive errors such as myopia and presbyopia is also said to increase in the upcoming years. For example, as per the International Myopia Institute (2023), 30% of the world is currently myopic and by 2050, the number of myopic people is said to grow to 50%, accounting for five billion. The aforementioned source further stated that myopia is more prevalent in East and South East Asia where countries such as South Korea, China, and Japan have a prevalence of 80% to 90%. In the case of presbyopia, as per the data cited by the World Health Organization in their World Report on Vision (2019), presbyopia accounted for approximately 1.8 billion cases across the globe in the year 2018.
Additionally, the rising geriatric population prone to the development of multiple eye disorders including cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and presbyopia, among others is further going to accelerate the ocular implants market. According to the data provided by the WHO (2023), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people. Also, people in the age group of 80 and above are estimated to triple between 2020 and 2050 to reach 426 million.
However, the lack of coverage of premium lenses and complications associated with surgical procedures and devices may act as restraining factors for the ocular implant market.
The ocular implants market reported a short period of a setback in market growth due to the implementation of lockdown as necessary measures to break the chain of COVID-19 infection transmission. The COVID-19 pandemic resulted in the massive reorganization of healthcare services and the carrying out of medical procedures. Many countries segregated medical procedures based on the need for urgent medical care to streamline the workflow during the COVID-19 crisis and saw various medical procedures considered elective being suspended. For instance, in March 2020, the American Academy of Ophthalmology (AAO) recommended ophthalmologists to stop all routine activities and restrict their treatment only to urgent and emergent cases; the AAO also recommended that clinical activities could be performed with continued caution in compliance with local regulations. Furthermore, the procedures of intra-ocular surgeries decreased as it became difficult to procure ocular implants during the lockdown period. This led to a decrease in product demand from regular levels. However, the resumption of activities across industries including the healthcare sector has been uplifting the ocular implants market and will drive growth during the forecast period from 2024-2030.
Ocular Implants Market Segment Analysis:
Ocular Implants Market by Type (Intraocular Lenses, Corneal Implants, Glaucoma Implants, Artificial Iris, and Others), Material (Biodegradable and Non-biodegradable), Application (Cataract, Glaucoma Surgery, Oculoplasty, Drug Delivery, Macular Degeneration, and Others), End-user (Hospitals, Eye Speciality Clinics, Ambulatory Surgical Centres), Geography (North-America, Europe, Asia-Pacific, Rest of the World).
In the type segment of the ocular implants market, the intraocular lenses category held the highest revenue share of 78% in 2022.
This can be attributed to the various properties, technical advantages, and increasing product development activities such as collaborations and regulatory approvals of intraocular lenses during the given forecast period.
IOLs are an excellent alternative to the excimer laser procedure (LASIK), they also eliminate the need for glasses or contact lenses post-surgery for most patients and the cataract will not return, as the lens has been removed.
IOLs such as aspheric IOLs eliminate the positive spherical aberration and offer patients improved contrast sensitivity, enhanced functional vision, and superior night driving ability.
Multifocal IOLs restore visual function and allow spectacle independence after their implantation with great levels of patient satisfaction and require less or no additional care or routine replacement.
Also, the toric IOLs are a type of monofocal IOL that helps correct corneal astigmatism of 1 D or more in cases undergoing cataract surgery and achieve spectacle independence for distance vision. For example, Auroflex Toric developed by Aurolab offers the perceivable benefit of superior quality vision for a patient with corneal astigmatism.
Extended Depth of Focus (EDOF or EDF), or Extended Range of Vision, is a new technology that has recently emerged in the treatment of Presbyopia-correcting IOLs and works by creating a single elongated focal point to enhance "range of vision" or "depth of focus."
Thereby, considering the growing demand for this product type, numerous new products are being launched in the market. For example, In May 2022, Ophtec BV introduced the Precizon Presbyopic Toric IOL. In November 2020, HumanOptics launched the trifocal posterior chamber IOL for presbyopia correction, TRIVA in Europe. In September 2019, BVI®, through its PhysIOL subsidiary, launched FineVision Triumf- the first and only Trifocal EDOF IOL in the European market.
Therefore, considering the advantages associated with intraocular implants and their growing popularity, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global ocular implants market during the forecast period.
North America is expected to dominate the overall Ocular Implants Market:
Among all the regions, North America held the largest share of 45.18% in 2022. This can be ascribed to the growing prevalence of eye disorders and refractive errors such as cataracts, glaucoma, myopia, presbyopia, and others.
As per the National Diabetics Statistics Report by the Centers for Disease Control and Prevention (CDC, 2020), about 34.2 million Americans had diabetes in 2020. The report further stated that approximately 88 million Americans showed pre-diabetes levels. The CDC considers diabetes to be one of the major risk factors that may lead to glaucoma development.
In addition, according to the National Eye Institute, 2020, the United States recorded 7.7 million diabetic retinopathy cases and 24 million cataract cases in 2020, and it is expected to reach 11.3 million and 38 million, respectively, by 2030.
A cataract is the major cause of visual impairment, and geriatric ocular issues have been emerging as potential factors in the past few years in developing countries.
All the above-stated ophthalmic issues will require ocular implants at some point, for their correction, which is expected to increase the demand for ocular implants.
In addition to a large patient pool associated with refractive errors in the North American region, high consumer awareness, new market launches, and the presence of a highly potent market in terms of product development are also some key factors driving the growth of the North American ocular implants market. For instance, in July 2020, the United States Food and Drug Administration approved Allergan's drug-releasing implant, DURYSTA, for administration within the cavities of the eye to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Therefore, the above-mentioned factors are going to bolster the North America ocular implant markets.
Ocular Implants Market Key Players:
Some of the key market players operating in the Ocular Implants market include Alcon, Johnson & Johnson Services Inc., Bausch Health Companies Inc., ZEISS International, Glaukos Corporation, AbbVie Inc., MORCHER® GmbH, HumanOptics Holding AG, Alimera Sciences, Advanced Artificial Eyes, Erickson Laboratories, Midwest Eye Laboratories, Inc., EyeYon, EyePoint Pharmaceuticals, Inc., HOYA Corporation, SMR Ophthalmic Pvt. Ltd, Gulden Ophthalmics, AJL Ophthalmic S.A., KeraMed, Inc., Innovia Medical, and others.
Recent Developmental Activities in the Ocular Implants Market:
In April 2022, STAAR SURGICAL announced the launch of the EVO Vision Implantable Collamer Lens at the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Washington D.C.
In November 2022, Alcon Inc. took over Invantis Inc., which specializes in glaucoma ocular devices that are micro-invasive, in California to expand its glaucoma surgical implants segment.
In May 2020, Bausch+Lomb, a part of Bosch Health Companies Inc., announced the European launch of LuxSmart and LuxGood Preloaded Intraocular lenses. Some of the features of these lenses are their monofocal periphery, acrylic hydrophobicity along with UV light protection.
Key Takeaways from the Ocular Implants Market Report Study
Market size analysis for current ocular implants market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the ocular implant market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years.
Key companies dominating the global ocular implants market.
Various opportunities available for the other competitor in the ocular implants market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current ocular implants market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for ocular implant market growth in the coming future?
Target Audience who can be benefited from this Ocular Implants Market Report Study
Ocular Implants providers
Research organizations and consulting companies
Ocular Implants -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in ocular implants
Various end users who want to know more about the ocular implants market and the latest technological developments in the ocular implants market.
Frequently Asked Questions for the Ocular Implants Market:
Ocular implants are small devices designed to be inserted into the eye, made of medical-grade plastic acrylic. Ocular implants form a part of surgical procedures that help in the fixation of cataracts and other vision impairments such as glaucoma, presbyopia, myopia, etc.
The global ocular implants market was valued at USD 5,060.43 million in 2023, growing at a CAGR of 4.51% during the forecast period from 2024 to 2030 to reach USD 6,561.46 million by 2030.
The ocular implants market is expected to grow significantly owing to factors such as a rise in the prevalence of eye disorders such as cataracts, glaucoma, presbyopia, myopia, and others coupled with a rising geriatric population globally. The rapidly growing technological advancements taking place in the ocular implants market with better technologies for delivering safe and biocompatible implants are further expected to result in appreciable revenue growth in the ocular implants market during the given forecast period (2024-2030).
Some of the key market players operating in the ocular implants market include Alcon, Johnson & Johnson Services Inc., Bausch Health Companies Inc., ZEISS International, Glaukos Corporation, AbbVie Inc., MORCHER® GmbH, HumanOptics Holding AG, Alimera Sciences, Advanced Artificial Eyes, Erickson Laboratories, Midwest Eye Laboratories, Inc., EyeYon, EyePoint Pharmaceuticals, Inc., HOYA Corporation, SMR Ophthalmic Pvt. Ltd, Gulden Ophthalmics, AJL Ophthalmic S.A., KeraMed, Inc., Innovia Medical, and others.
North America is expected to dominate the overall ocular implants market during the forecast period, 2024 to 2030. This can be ascribed to the presence of a large number of cases having eye disorders such as glaucoma, cataract, presbyopia, and myopia along with the rising geriatric population in the region. In addition, it is a highly potent market in terms of technological developments and launches along with the presence of key market players among other factors in the region.